Literature DB >> 8938657

Effects of the 5-HT2 receptor antagonist ritanserin on halothane-induced increase of inositol phosphates in porcine malignant hyperthermia.

A Richter1, J Scholz, W Löscher, P H Tonner, F Wappler.   

Abstract

Recent studies have shown a significant increase of inositol phosphates (IPs) in skeletal muscle during episodes of halothane-induced malignant hyperthermia (MH) in pigs. After treatment with dantrolene and disappearance of MH crisis the IP concentrations returned to basal levels. In order to examine if the increase of IPs during halothane-induced MH may be related to an enhanced IP synthesis in response to activation of 5-HT2 (5-hydroxytryptamine) receptors, the effects of ritanserin, a selective 5-HT2 receptor antagonist, on IP levels were investigated. Biopsies of skeletal muscle of the hindlimbs were obtained in random order and IPs were determined in homozygous MH-susceptible (MHS) and MH-non-susceptible (MHN) swine in the following order: (1) basal, (2) after treatment with ritanserin (2.0 mg/kg), (3) after halothane challenge (3 vol% for 20 min). Basal concentrations of all IPs were higher in MHS than in MHN swine. Ritanserin did not cause any significant changes of IP levels compared to the basal concentrations in MHS and MHN pigs. In MHS pigs, ritanserin did not prevent a halothane-induced MH-crisis. After halothane challenge, 1,3,4-IP3, 1,3,4,6-IP4 and 1,3,4,5-IP4 levels were increased in MHS (during MH crisis) vs. basal concentrations, whereas no changes were found in MHN pigs. Since the increases of IP levels in MHS pigs during MH crisis found in the present study were comparable to those without pretreatment with ritanserin, shown by recent studies, it may be concluded that ritanserin does not prevent the increase of IPs during a halothane-induced MH. Thus, the present data indicate that increases of IP levels during halothane-induced MH in swine are due to other mechanisms than 5-HT mediated enhancement of IP synthesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938657     DOI: 10.1007/bf00170833

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Inositol-1,4,5-trisphosphate and malignant hyperthermia.

Authors:  J Scholz; U Troll; J Schulte am Esch; E Hartung; M Patten; P Sandig; W Schmitz
Journal:  Lancet       Date:  1991-06-01       Impact factor: 79.321

2.  Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia.

Authors:  J E Fletcher; L Tripolitis; M Hubert; G M Vita; R C Levitt; H Rosenberg
Journal:  Br J Anaesth       Date:  1995-09       Impact factor: 9.166

3.  Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine.

Authors:  P S Foster; E Gesini; C Claudianos; K C Hopkinson; M A Denborough
Journal:  Lancet       Date:  1989-07-15       Impact factor: 79.321

4.  Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia.

Authors:  W Löscher; U Witte; G Fredow; M Ganter; K Bickhardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

5.  Hypersensitive response of malignant hyperthermia-susceptible skeletal muscle to inositol 1,4,5-triphosphate induced release of calcium.

Authors:  J R López; C Pérez; N Linares; P Allen; A Terzic
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

6.  Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.

Authors:  F Wappler; N Roewer; A Köchling; J Scholz; W Löscher; M Steinfath
Journal:  Anesthesiology       Date:  1996-06       Impact factor: 7.892

7.  The behavioural responses to 8-OH-DPAT, ipsapirone and the novel 5-HT1A receptor agonist Bay Vq 7813 in the pig.

Authors:  W Löscher; U Witte; G Fredow; J Traber; T Glaser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

8.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

9.  A possible role for inositol 1,4,5-trisphosphate (IP3) in malignant hyperthermia.

Authors:  C M Steinmann
Journal:  Med Hypotheses       Date:  1994-03       Impact factor: 1.538

10.  Evidence for genetic heterogeneity in malignant hyperthermia susceptibility.

Authors:  R C Levitt; N Nouri; A E Jedlicka; V A McKusick; A R Marks; J G Shutack; J E Fletcher; H Rosenberg; D A Meyers
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.